NPR3 and irritable bowel syndrome: Linaclotide regulates guanylate cyclase C (GCC) and is used in the treatment of irritable bowel syndrome (IBS), but has not been demonstrated to regulate autoimmune diseases such as inflammatory bowel disease (IBD), making this study the first to examine its potential as a scaffold in IBD.